Drug Profile
Research programme: cannabinoid-based therapeutics - CURE Pharmaceutical/SciSparc/Assuta Medical Center
Alternative Names: Dronabinol/palmitoylethanolamide combination therapies - Assuta Medical Center/ CURE Pharmaceutical/SciSparc; Dronabinol/palmitoylethanolamide combination therapies - CURE Pharmaceutical/SciSparc/Assuta Medical Center; Dronabinol/palmitoylethanolamide combination therapies - SciSparc/ Assuta Medical Center/CURE PharmaceuticalLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Assuta Medical Center; Cure Pharmaceutical; Therapix Biosciences
- Developer Assuta Medical Center; Cure Pharmaceutical; SciSparc
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sleep disorders
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Sleep-disorders in Israel (PO, Film)
- 28 Aug 2021 No recent reports of development identified for research development in Sleep-disorders in USA (PO, Film)
- 28 Jan 2021 Therapix Biosciences is now called SciSparc